{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T05:06:20Z","timestamp":1775365580862,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001275","name":"The Oak Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0183821","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T17:39:49Z","timestamp":1504028389000},"page":"e0183821","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1371","volume":"12","author":[{"given":"Karina Glies Vincents","family":"Johansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Tarp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Astrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne K.","family":"Pagsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"ref1","unstructured":"World Health Organization (2014) ICD-10 Version:2014."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10401230490281366","article-title":"Impulse control disorders: clinical characteristics and pharmacological management","volume":"16","author":"JE Grant","year":"2004","journal-title":"Ann Clin Psychiatry"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2011.00001","article-title":"Impulse control disorders: updated review of clinical characteristics and pharmacological management","volume":"2","author":"L Schreiber","year":"2011","journal-title":"Front Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5. 947 p.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"JP Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"J Lazarou","year":"1998","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"M Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/pds.1565","article-title":"Adverse drug reaction-related hospitalisations: a population-based cohort study","volume":"17","author":"CS van der Hooft","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref9","first-page":"CD002022","article-title":"Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal","author":"L Gowing","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings","author":"DE Jonas","year":"2014"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"DE Jonas","year":"2014","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: a review of its use in the treatment of alcohol dependence","volume":"27","author":"GM Keating","year":"2013","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/00003643-200106000-00002","article-title":"Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials","volume":"18","author":"F Kjellberg","year":"2001","journal-title":"Eur J Anaesthesiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00023210-200418080-00002","article-title":"Pharmacotherapy of alcohol dependence: a review of the clinical data","volume":"18","author":"K Mann","year":"2004","journal-title":"CNS Drugs"},{"key":"ref15","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","author":"S Rosner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"ref16","first-page":"CD001867.","article-title":"Opioid antagonists for alcohol dependence","author":"M Srisurapanont","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","unstructured":"European Medicines Agency (2012) Assessement report Selincro. 1\u201373."},{"key":"ref18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1192\/bjp.bp.110.078105","article-title":"Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study","volume":"197","author":"JE Grant","year":"2010","journal-title":"Br J Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","volume":"31","author":"S Karhuvaara","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"JE Grant","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"A Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"MJ Bradburn","year":"2007","journal-title":"Stat Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"SG Thompson","year":"2002","journal-title":"Stat Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","article-title":"Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers","volume":"28","author":"DJ Drobes","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1530-0277.2008.00735.x","article-title":"Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers","volume":"32","author":"AJ Arias","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.npp.1300101","article-title":"A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene","volume":"28","author":"DJ Drobes","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0376-8716(00)80005-8","article-title":"Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans","volume":"60","author":"HE Jones","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-008-1235-3","article-title":"Predicting response to opiate antagonists and placebo in the treatment of pathological gambling","volume":"200","author":"JE Grant","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"W van den Brink","year":"2013","journal-title":"Alcohol Alcohol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","article-title":"Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study","volume":"28","author":"W van den Brink","year":"2014","journal-title":"J Psychopharmacol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"BJ Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"BJ Mason","year":"1994","journal-title":"Alcohol Clin Exp Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"RF Anton","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"K Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"A Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref38","unstructured":"Edison Investment Research (2011) Biotie Therapies Corp. Update 21 June 2011."},{"key":"ref39","unstructured":"Somaxon Pharmaceuticals I (2015) Somaxon Pharmaceuticals Reports Positive Results From a Pilot Phase 2 Study of Oral Nalmefene in Smoking Cessation."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.15288\/jsa.2000.61.220","article-title":"Drinking in alcoholics following an alcohol challenge research protocol","volume":"61","author":"DJ Drobes","year":"2000","journal-title":"J Stud Alcohol"},{"key":"ref41","unstructured":"H.Lundbeck A\/S (2015) Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0183821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T22:13:31Z","timestamp":1570054411000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0183821"}},"subtitle":[],"editor":[{"given":"Vincenzo","family":"DeLuca","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0183821","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}